The first COVID-19 vaccine developed in the southern hemisphere commences human trials in Adelaide today.
40 healthy participants aged between 18 and 65 – who’ve already been pre-screened – are taking part.
They will receive two doses of Covax-19 or a placebo three weeks apart.
Participants will then have blood tests to measure protective antibody and T cell responses induced by the vaccine.
According to Sharen Pringle from Vaxine – the company behind the vaccine:
“This was not an overnight success with 18 years of hard development work going into the pandemic vaccine platform that delivered COVAX-19®.
“We would not have achieved this key milestone in development of COVAX-19® without support from many key partners, who will all be acknowledged through Vaxine’s website.”
The Phase 1 trial will provide initial safety and immune response data on COVAX-19® vaccine and is being conducted by the PARC clinical trial unit at the Royal Adelaide Hospital.
